Recent Updates
Recently added Catalysts
CORT Negative Sentiment Score: 20/100

Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

Key Takeaway: Corcept Therapeutics is facing a class action lawsuit following a major drop in its stock price when the FDA issued a Complete Response Letter for its new product candidate, relacorilant. Investors who incurred losses exceeding $100,000 during the Class Period from October 31, 2024, to December 30, 2025, are reminded of the deadline to file lead plaintiff applications by April 21, 2026. The lawsuit accuses the company and its executives of failing to disclose critical information regarding the likelihood of FDA approval for relacorilant. Shareholders can seek further information through ClaimsFiler or Kahn Swick & Foti law firm.

Market Sentiment Analysis

CONCERNS & RISKS

  • Corcept is facing a class action lawsuit for failing to disclose material information.
  • The company experienced a significant drop in stock price, plummeting 50.4%.
  • The FDA issued a Complete Response Letter regarding relacorilant, indicating a lack of evidence for effectiveness.

Full Press Release Details

NEW ORLEANS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Corcept investors should visit us at https://claimsfiler.com/cases/nasdaq-cort-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Corcept and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The complaint alleges that, during the Class Period, the Company represented to investors that there was a high likelihood that one of its lead new product candidates, relacorilant, would receive approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s New Drug Application (“NDA”) submission. However, on December 31, 2025, the Company disclosed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant and that it had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.”
On this news, the price of Corcept’s shares plummeted by $35.40 per share, or 50.4%, from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025.
The case is Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline for filing lead plaintiff applications?

The deadline to file lead plaintiff applications is April 21, 2026.

What is the lawsuit against Corcept about?

Corcept is accused of failing to disclose material information during the Class Period.

How much did Corcept's share price drop?

The share price dropped by $35.40, or 50.4% after FDA news.

Where can investors find more information?

Investors can visit https://claimsfiler.com/cases/nasdaq-cort-1/ for details.

Who are the lawyers involved in the case?

Lawyers at Kahn Swick & Foti, LLC are handling the case.

Last updated: Feb 26, 2026